NeoProteomics is a provider of research services and tools that help clients unravel the complexities of pharmaceutical and biological research. Headquartered in Cleveland, Ohio, the company was founded by Dr. Mark Chance, Director of the Center for Proteomics and Bioinformatics at Case Western Reserve University (CWRU), John L. H. Schenkel, Jr. and Steven Chance in 2006, to evaluate and commercialize technologies developed at CWRU. NeoProteomics has licensed an attractive IP portfolio from CWRU, which serves as the foundation of cutting edge services that help researchers increase the speed and accuracy of their biologics and small molecular drug development. NeoProteomics currently provides expert services and tools to numerous partner companies and research laboratories worldwide.
Former Executive Vice President and General Counsel of Teleflex Corporation
Handles all legal, IP, patents, and contractual engagements
Structural Mass Spectrometry Team
Janna Kiselar, Ph.D. Project Manager
Recognized expert in Structural Biology and CL-MS with over 20 years of experience with numerous collaborations and publications.
Serves as Project Manager and primary point of contact for all client engagements.
Parminder Kaur, Ph.D. Principal Scientist
Over 10 years of research experience designing efficient algorithms on various aspects of mass spectrometry data interpretation including tools to analyze structures of biologics using mass spectrometry approaches that can define structure and determine equivalency.
Performs and directs all data anlaysis and report drafting. Engages in business development and customer acquisition activities.
NeoProteomics, Inc. | 11000 Cedar Ave. | Cleveland, OH 44106|Contact Us